SARCLISA Patient Profiles

Explore the range of patient types who may be appropriate for treatment with SARCLISA

Newly diagnosed

Relapsed or refractory

Patients with NDMM not eligible for transplant who may be appropriate for SARCLISA + VRd (IMROZ)

A headshot of Kenneth, a 74-year-old White man. A headshot of Kenneth, a 74-year-old White man.

Meet Kenneth, a 74-year-old patient who is prioritizing efficacy at 1L

Hypothetical patient case

Patient information

A silhouette icon of a person.

Age
74

A mobility icon.

ECOG PS
1

An R-ISS icon.

R-ISS
II

An icon of a chromosome.

Cytogenetic risk
Standard

Relevant information

  • Well-controlled type II diabetes, no organ damage
  • Retired, spends free time with his grandchildren. Moderately active, uses cane occasionally

1L=first line; ECOG PS=Eastern Cooperative Oncology Group performance status; R-ISS=Revised International Staging System; VRd=bortezomib, lenalidomide, dexamethasone.

View patient profile

Review the data for SARCLISA + VRd in patients like Kenneth

Explore the IMROZ Trial
A headshot of Mei, a 79-year-old Asian-American woman. A headshot of Mei, a 79-year-old Asian-American woman.

Meet Mei, a 79-year-old patient who is eager to challenge her high-risk prognosis

Hypothetical patient case

Patient information

A silhouette icon of a person.

Age
79

A mobility icon.

ECOG PS
2

An R-ISS icon.

R-ISS
III

An icon of a chromosome.

Cytogenetic risk
High

Relevant information

  • Mild renal impairment (eGFR=50 mL/min/1.73 m2)
  • Lives with family, manages most activities of daily living independently

eGFR=estimated glomerular filtration rate.

View patient profile

Review the data for SARCLISA + VRd in patients like Mei

Explore the IMROZ Trial

RRMM patients who may be appropriate for SARCLISA + Kd (IKEMA)

A headshot of Maisie, a 68-year-old White woman. A headshot of Maisie, a 68-year-old White woman.

Meet Maisie, a 68-year-old patient who is motivated to respond to her first relapse

Hypothetical patient case

Patient information

A silhouette icon of a person.

Age
68

A mobility icon.

ECOG PS
1

An icon of an arrow deflecting off a surface.

Refractory to
lenalidomide

An icon of a chromosome.

Cytogenetic risk
Standard

Relevant information

  • Anti-CD38 naïve (received VRd induction followed by lenalidomide maintenance at 1L)
  • Aggressive disease at relapse
  • Retired, lives with husband. Moderately active, gardens in her free time

1L=first line; ECOG PS=Eastern Cooperative Oncology Group performance status; Kd=carfilzomib and dexamethasone; RRMM=relapsed or refractory multiple myeloma; VRd=bortezomib, lenalidomide, dexamethasone.

View patient profile

Review the data for SARCLISA + Kd in patients like Maisie

Explore the IKEMA Trial
A headshot of Franklin, a 70-year-old Black man. A headshot of Franklin, a 70-year-old Black man.

Meet Franklin, a 70-year-old patient who is intent on challenging his high-risk prognosis at first relapse

Hypothetical patient case

Patient information

A silhouette icon of a person.

Age
70

A counterclockwise arrow icon.

Early relapse
(<1 year)

An icon of a pair of kidneys.

Renal impairment
(eGFR 41 mL/
min/1.73 m2)

An icon of a chromosome.

High cytogenetic risk
iFISH positive for t(4;14), 1q21+

Relevant information

  • Anti-CD38 naïve (received VRd induction followed by ASCT and Rd maintenance at 1L)
  • Aggressive disease at relapse
  • Lives with wife, volunteers at local food pantry

ASCT=autologous stem cell transplant; eGFR=estimated glomerular filtration rate; iFISH=interphase fluorescence in situ hybridization; Rd=lenalidomide and dexamethasone.

View patient profile

Review the data for SARCLISA + Kd in patients like Franklin

Explore the IKEMA Trial

An RRMM patient who may be appropriate for SARCLISA + Pd (ICARIA-MM)

A headshot of Thomas, a 76-year-old White man. A headshot of Thomas, a 76-year-old White man.

Meet Thomas, a 76-year-old patient who is motivated to get back into remission after relapsing for a second time

Hypothetical patient case

Patient information

A silhouette icon of a person.

Age
70

A mobility icon.

ECOG PS
1

An icon of an arrow deflecting off a surface.

Refractory to
lenalidomide

An icon of a pair of kidneys.

Renal impairment
(eGFR 44 mL/min/1.73 m2)

Relevant information

  • Anti-CD38 naïve (received IMiD + PI-based regimens in 1L and 2L)
  • Aggressive disease at relapse, about to receive third line of therapy
  • Lives with family, helps look after his grandchildren

2L=second line; IMiD=immunomodulatory drug; PI=proteasome inhibitor; Pd=pomalidomide and dexamethasone.

View patient profile

Review the data for SARCLISA + Pd in patients like Thomas

Explore the ICARIA-MM Trial